Immurait-Ll2Mab Antibodies

Target Information

Immurait-Ll2Mab is a biosimilar that targets CD22. CD22 (BL-CAM) is a type 1 integral membrane glycoprotein with molecular weight of 130 to 140 kDa. CD22 is expressed in both the cytoplasm and cell membrane of B-lymphocytes. CD22 antigen appears early in B-cell lymphocyte differentiation at approximately the same stage as the CD19 antigen. Unlike other B-cell markers, CD22 membrane expression is limited to the late differentiation stages comprised between mature B cells (CD22+) and plasma cells (CD22-), and may thus prove useful in phenotyping mature leukemias. CD22 is also strongly expressed in hairy cell leukemia. CD22 preferentially binds to alpha2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B cell antigen receptor signaling. CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. CD22 is also strongly expressed in hairy cell leukemia. CD22 is also positive in diffuse large B-cell lymphoma and nodular lymphocyte predominance Hodgkin's lymphoma, but negative in classical Hodgkin's lymphoma.

Synonyms

ImmuRAIT-LL2; 131I-IMMU-LL2